Capricor Therapeutics Securities Fraud Lawsuit Opportunity for Investors
Investors have the opportunity to lead a securities fraud lawsuit against Capricor Therapeutics, Inc. The lawsuit alleges violations of securities law provisions.
National shareholder rights litigation firm Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR). The lawsuit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
The core of the complaint centers on allegedly false and misleading statements made by the company regarding its exosome-based therapy, CAP-1002. Specifically, the lawsuit claims that Capricor Therapeutics failed to adequately disclose information about the results of its clinical trials for CAP-1002 and its potential to treat Duchenne muscular dystrophy.
SBS has issued a call for purchasers of Capricor Therapeutics securities between 2021 and 2023 to come forward. These investors may have the opportunity to serve as lead plaintiff in the class action. The firm emphasizes that no wrongdoing has been proven, and the extent of the claims will be determined through the litigation process.
Capricor Therapeutics investors who have experienced significant losses are advised to assess their legal recourse. The allegations suggest potential misrepresentations made by the company to its shareholders concerning its drug development pipeline.